https://shikonininhibitor.com/....admission-pulse-rate
The study revealed a substantial financial impact on Chinese COPD patients stemming from COPD exacerbations, pneumonia, and hospitalizations. A considerable reduction in economic burden was observed in individuals who received the influenza vaccine, the 23-valent pneumococcal polysaccharide vaccine (PPSV23), or both. Our research corroborates existing data suggesting that COPD patients in China should be given
Мне нравится
Комментарий
Перепост
